Advertisement

Hepatic sinusoidal obstruction syndrome secondary to intravesical instillation of mitomycin-C

  • Álvaro Marchán-López
  • María Asunción Pérez-Jacoiste AsínEmail author
  • Justino Jiménez-Almonacid
  • Marta Arroyo-López
  • Juan Justo-Quintas
Case Report
  • 32 Downloads

Abstract

Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening complication with high mortality rate. Even if it is more commonly described after hematopoietic stem-cell transplant, hepatic-SOS may occur following the use of certain chemotherapeutic agents. Mitomycin-C has been previously identified as a causal agent when administered intravenously at high doses. We report herein the first case of hepatic-SOS due to intravesical instillation of mitomycin-C, after a traumatic urinary catheterization with significant hematuria. Although this procedure is usually considered safe, without the systemic side effects related to intravenous administration of the drug, clinicians must be aware of its potential risks to facilitate an early diagnosis, avoid a delay in the withdrawal of the causative drug and set up an appropriate therapy as soon as possible.

Keywords

Intravesical instillation Mitomycin-C Bone marrow aplasia Hepatic sinusoidal obstruction syndrome 

Abbreviations

SOS

Sinusoidal obstruction syndrome

G-CSF

Granulocyte-colony-stimulating factor

Notes

Author contributions

All the authors made substantial contributions to the conception and design of the work. Marchán-López and Pérez-Jacoiste Asín wrote the manuscript; Pérez-Jacoiste Asín and Justo-Quintas critically reviewed the manuscript; Jiménez-Almonacid provided the histological diagnosis; Arroyo-López performed and provided data of the transjugular hepatic-vein catheterization; Marchán-López and Pérez-Jacoiste Asín were in charge of medical care of the patient. All the authors approved the final draft of the manuscript to be published. All the authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy and integrity of any part of the work are appropriately investigated and resolved.

Funding

No funding sources.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Human/animal Rights

All the procedures have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendements.

Informed consent

The family of the patient gave informed consent for the publication of the case. Confidentiality was preserved.

References

  1. 1.
    Babjuk M, Oosterlinck W, Sylvester R, et al. European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Thrasher JD, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am. 1992;19:529–39.PubMedGoogle Scholar
  3. 3.
    Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl. 2016;22:400–9.CrossRefGoogle Scholar
  4. 4.
    Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.CrossRefPubMedGoogle Scholar
  5. 5.
    DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27–422.CrossRefPubMedGoogle Scholar
  6. 6.
    Rio B, Andreu G, Nicod A, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood. 1986;67:1773–6.CrossRefGoogle Scholar
  7. 7.
    Lazarus HM, Gottfried MR, Herzig RH, et al. Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer. 1982;49:1789–95.CrossRefPubMedGoogle Scholar
  8. 8.
    Carft PS, Pembrey RG. Veno-occlusive disease of the liver following chemotherapy with mitomycin C and doxorubicin. Aust N Z J Med. 1987;17:449–51.CrossRefGoogle Scholar
  9. 9.
    Robitaille N, Lacroix J, Alexandrov L, et al. Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a canadian blood and marrow transplant group trial. Biol Blood Marrow Transpl. 2013;19:468–73.CrossRefGoogle Scholar
  10. 10.
    Bönig H, Burdach S, Göbel U, et al. Growth factors and hemostasis: differential effects of GM-CSF and G-CSF on coagulation activation–laboratory and clinical evidence. Ann Hematol. 2001;80:525–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Nieuwenhuijzen JA, Bex A, Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol. 2003;43:711–2.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  • Álvaro Marchán-López
    • 1
  • María Asunción Pérez-Jacoiste Asín
    • 1
    Email author
  • Justino Jiménez-Almonacid
    • 2
  • Marta Arroyo-López
    • 3
  • Juan Justo-Quintas
    • 4
  1. 1.Department of Internal MedicineHospital Universitario 12 de Octubre, Instituto de Investigacion Hospital 12 de Octubre (i+12), Universidad ComplutenseMadridSpain
  2. 2.Department of PathologyHospital Universitario 12 de OctubreMadridSpain
  3. 3.Department of Vascular RadiologyHospital Universitario 12 de OctubreMadridSpain
  4. 4.Department of UrologyHospital Universitario 12 de OctubreMadridSpain

Personalised recommendations